+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

From
From
From
From
Axial Spondyloarthritis (axSpA) - Pipeline Insight - 2020 - Product Thumbnail Image

Axial Spondyloarthritis (axSpA) - Pipeline Insight - 2020

  • Clinical Trials
  • November 2020
  • 60 pages
From
Ulcerative Colitis - Pipeline Insight, 2021 - Product Thumbnail Image

Ulcerative Colitis - Pipeline Insight, 2021

  • Clinical Trials
  • May 2021
  • 200 pages
From
From
Psoriasis - Pipeline Review, H2 2020 - Product Thumbnail Image

Psoriasis - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 956 pages
From
From
Juvenile Idiopathic arthritis (JIA) - Pipeline Insight, 2020 - Product Thumbnail Image

Juvenile Idiopathic arthritis (JIA) - Pipeline Insight, 2020

  • Clinical Trials
  • February 2020
  • 106 pages
From
From
From
From
From
From
From
From
Diabetic Neuropathy Global Clinical Trials Review, H1, 2019 - Product Thumbnail Image

Diabetic Neuropathy Global Clinical Trials Review, H1, 2019

  • Clinical Trials
  • May 2019
  • 323 pages
From
From
Loading Indicator
adroll